2022
Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury
Sprangers B, Leaf DE, Porta C, Soler MJ, Perazella MA. Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury. Nature Reviews Nephrology 2022, 18: 794-805. PMID: 36168055, DOI: 10.1038/s41581-022-00630-8.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsAcute kidney injuryKidney injuryKidney biopsyAcute tubulo-interstitial nephritisImmune-related adverse eventsConcomitant anticancer therapyTubulo-interstitial nephritisEffector T cellsEvaluation of patientsLoss of toleranceCheckpoint inhibitorsPartial remissionPermanent discontinuationAdverse eventsMost patientsAppropriate treatmentEarly initiationT cellsClinical practiceFavorable responsePatientsAccurate diagnosisCancer treatmentAnticancer therapy
2021
Checkpoint inhibitor therapy-associated acute kidney injury: time to move on to evidence-based recommendations
Perazella MA, Sprangers B. Checkpoint inhibitor therapy-associated acute kidney injury: time to move on to evidence-based recommendations. Clinical Kidney Journal 2021, 14: 1301-1306. PMID: 33970161, PMCID: PMC8087122, DOI: 10.1093/ckj/sfab052.Peer-Reviewed Original ResearchAcute kidney injuryImmune checkpoint inhibitorsAcute tubulointerstitial nephritisKidney biopsyImmune-related adverse eventsVall d'Hebron University HospitalSingle-center studyNoninvasive diagnostic markerEvidence-based recommendationsAKI patientsICI rechallengeNephrology servicesCheckpoint inhibitorsICI treatmentKidney injuryAdverse eventsTubulointerstitial nephritisNonhematologic malignanciesUniversity HospitalTreatment protocolClinical practicePatientsOptimal managementDiagnostic markerCancer treatment